Carlo Resteghini
University of Milan
CancerInternal medicineSurgeryPathologyOncologyRetrospective cohort studyLenvatinibHead and neck cancerInduction chemotherapyChemotherapyHead and neck squamous-cell carcinomaSalivary gland cancerDacomitinibMucositisAdenoid cystic carcinomaCetuximabCancer researchRadiation therapyMedicineGastroenterology
85Publications
13H-index
487Citations
Publications 85
Newest
#1Stefano Cavalieri (University of Milan)H-Index: 8
#2Elena Colombo (University of Milan)H-Index: 13
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 15 authors...
OBJECTIVE: To capture and monitor flu-like symptoms in relation to the clinical characteristics and the oncologic treatment of a large head and neck cancer (HNC) patient cohort during the Coronavirus disease 2019 (COVID-19) pandemic. METHODS: Patients were monitored through by 2 rounds of interviews. Clinical characteristics of patients with no symptoms (group 0) and of those reporting ⩾1 (group A), ⩾3 (group B), or ⩾5 symptoms (group C) were analyzed. Patients with ⩾1 symptom at both in...
Source
#1Francesca Platini (University of Milan)H-Index: 6
#2Stefano Cavalieri (University of Milan)H-Index: 8
Last. Laura D. Locati (University of Milan)H-Index: 31
view all 12 authors...
PURPOSE Radioactive-iodine (RAI)-resistant differentiated thyroid cancer (DTC) patients benefit from multi-kinase inhibitors (MKIs), such as lenvatinib. Incidence of treatment-related (TR) late toxicities has been not yet described. METHODS From January 2015 to June 2019 we retrospectively reviewed clinical records of patients with RAI-resistant DTC treated with lenvatinib at Istituto Nazionale dei Tumori (Milan, Italy). New side effect of any grade, appeared after 12 months of lenvatinib, was d...
Source
PURPOSE To describe the management and outcomes of loco-regionally advanced (stages III-IV) laryngeal cancer (LRALC) in elderly patients. METHODS Clinical records of 88 LRALC patients treated at our Institution from 2002 to 2017 were retrospectively reviewed. Patients were divided in 2 subgroups: age > 65 years (elderly) and age ≤ 65 years (controls). Survivals were estimated with Kaplan-Meier method and compared with log-rank test, multivariate analysis were performed with Cox proportional haza...
Source
#2G. InfanteH-Index: 1
Last. E. OrlandiH-Index: 3
view all 15 authors...
Source
#1Cristiana BergaminiH-Index: 20
#2Stefano CavalieriH-Index: 8
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 11 authors...
Introduction:Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are established procedures for treating hepatocellular cancer and selected malignancies with liver metastasis. ...
Source
#1Stefano CavalieriH-Index: 8
#2Luigi MarianiH-Index: 50
Last. Laura D. LocatiH-Index: 31
view all 17 authors...
Abstract Background Distant metastases in adenoid cystic carcinoma (ACC) are common. There is no consensus on the management of metastatic disease because no therapeutic approach has demonstrated improvement in overall survival (OS) and because of prolonged life expectancy. The aim of this study is to build and validate a prognostic nomogram for metastatic ACC patients. Methods The study end-point was OS, measured from the date of first metastatic presentation to death/last follow-up. A retrospe...
4 CitationsSource
#1Lisa LicitraH-Index: 68
#2Carlo ResteghiniH-Index: 13
Last. Paolo Bossi (University of Brescia)H-Index: 37
view all 3 authors...
The inclusion of systemic therapy in the multimodal approach of locally advanced sinonasal cancers, at least in some selected histologies, may improve locoregional control and reduce the frequency of distant metastasis, allowing longer survival. Response to induction chemotherapy is a strong prognostic factor for a patient's outcome and it may improve disease control by surgery and radiation. Concurrent chemoradiation aims at increasing locoregional control in squamous cell cancer of the head an...
Source
#1Ester OrlandiH-Index: 22
Last. Piero Nicolai (UNIPD: University of Padua)H-Index: 62
view all 8 authors...
Malignancies of the anterior skull base are rare and recur in 40-80% of treated cases, varying with substantial variance according to histology, stage at primary diagnosis, and other factors. Most recurrences manifest within 2-5 years after primary treatment, but some histologies can relapse even decades after the first presentation. Management of recurrent anterior skull base tumors is challenging and a wide variety of treatment options are available. Similar to the primary setting, surgery is ...
Source
#1Francesca PlatiniH-Index: 6
#2Elisa OrtolanH-Index: 1
Last. Laura D. LocatiH-Index: 31
view all 19 authors...
e18577Background: ATC is a very aggressive disease. In the last years new insights on molecular profile of ATC have led to novel therapeutic options, primarily BRAF-targeted agents. Methods: From M...
1 CitationsSource
#1Carlo ResteghiniH-Index: 13
#2Paola Maggioni (University of Milan)H-Index: 4
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 4 authors...
2 CitationsSource